Invention Grant
- Patent Title: Recombinant polyclonal proteins targeting Zika and methods of use thereof
-
Application No.: US17469493Application Date: 2021-09-08
-
Publication No.: US11718660B2Publication Date: 2023-08-08
- Inventor: David Scott Johnson , Sheila Keating , Adam Shultz Adler , Michael Asensio , Kacy Stadtmiller , Emily Benzie , Ariel Niedecken , Angelica V. Medina-Cucurella , Rena Aviva Mizrahi , Yoong Wearn Lim
- Applicant: GigaGen, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: GigaGen, Inc.
- Current Assignee: GigaGen, Inc.
- Current Assignee Address: US CA San Carlos
- Agency: Fenwick & West LLP
- Main IPC: C07K14/00
- IPC: C07K14/00 ; C07K16/10 ; A61P31/14
Abstract:
Provided herein are compositions comprising recombinant polyclonal protein (RPP) derived from mammalian plasma cells and plasmablasts. Specifically, RPPs specific to Zika virus are provided. Also provided are the methods of using the RPP for treatment of viral infection and the methods of making the RPPs.
Public/Granted literature
- US20220064268A1 RECOMBINANT POLYCLONAL PROTEINS TARGETING ZIKA AND METHODS OF USE THEREOF Public/Granted day:2022-03-03
Information query
